Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen, +15

The Lancet

Subcutaneous EpcoritamabLymphoid NeoplasiaDose EscalationMedicineDermatology +2

VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration

Sandra van Wetering, Nadia van den Berk, Jaap D. van Buul, +5

American Journal of Physiology-Cell Physiology

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Ana Rio‐Machín, Tom Vulliamy, Nele Hug, +55

Nature Communications

Enhanced formation and survival of CD4⁺CD25^hiFoxp3⁺T-cells in chronic lymphocytic leukemia

Margot Jak, Margot Jak, Rogier Mous, +7

Leukemia & lymphoma/Leukemia and lymphoma

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study

Rosa Ruchlemer, Ronen Ben‐Ami, Maskit Bar‐Meir, +26

Mycoses

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, Rogier Mous, Michael Roost Clausen, +11

Blood

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P. Kater, Mark‐David Levin, Julie Dubois, +19

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyClinical Trials +8

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial

Martine E.D. Chamuleau, Coreline N. Burggraaff, Marcel Nijland, +29

Haematologica

ImmunologyMyc+ LbclPathologyPharmacotherapyImmunotherapy +14

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients

Rimke Oostvogels, Margot Jak, Reinier Raymakers, +2

British Journal of Haematology

<scp>R‐miniCHOP</scp> versus <scp>R‐CHOP</scp> in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

Diana Al-Sarayfi, Mirian Brink, Martine E.D. Chamuleau, +11

American Journal of Hematology

Elderly PatientsImmunologyPathologyNetherlands Cancer RegistryMetronomic Chemotherapy +14